Cost-effectiveness analyses and utility weights
Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles.
4 cost-effectiveness analyses and 5 studies reporting utility weights · 7 sources
Overview
| Item | Detail |
|---|---|
| Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. |
| Cost-effectiveness analyses | 4 |
| Studies reporting utility weights | 5 |
Cost-effectiveness analyses
Analyses of Hovilpri (pritelivir and AIC316)
No evidence found.
Treatments for the same indication
No evidence found.
The same disease in other populations or settings
Acyclovir prophylaxis versus no acyclovir in pregnant women with a history of genital herpes simplex virus infection, United States: Little and Caughey (2005)
Relevance: Evaluates acyclovir prophylaxis against no acyclovir in pregnant women with a history of diagnosed genital herpes simplex virus infection in the United States; acyclovir is one of the antivirals to which the infection in the Hovilpri indication is refractory.
Access: Not open access
Not quoted: The perspective, time horizon, discount rate, and cost year are reported in the full text, which this page does not quote.
“A decision analytic model was designed that compared acyclovir prophylaxis versus no acyclovir for women with a history of diagnosed genital herpes simplex virus infection but without recurrence in pregnancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sensitivity analysis and Monte Carlo simulations were performed to test for robustness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We found that 22,286 women must be treated to prevent 1 neonatal death, 8985 women to prevent 1 affected child, and 177 women to prevent 1 cesarean delivery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As compared with no acyclovir, acyclovir prophylaxis at 36 weeks of gestation saves approximately dollar 20 per person and increases total quality-adjusted life years by 0.01.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Monte Carlo simulation demonstrated acyclovir to be cost-effective 100% of the time and cost saving >99% of the time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Related diseases and analogous treatments
Maribavir versus investigator-assigned therapy for refractory cytomegalovirus infection after transplantation, United States: Schultz et al. (2024)
Relevance: Evaluates oral maribavir against investigator-assigned therapy (valganciclovir, ganciclovir, foscarnet, or cidofovir) for refractory cytomegalovirus infection after transplantation in the United States, a refractory herpesvirus infection whose comparator arm includes the foscarnet and cidofovir of the PRIOH-1 Part C investigator's-choice arm.
Access: Free full text
Letermovir prophylaxis versus pre-emptive therapy for cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients, United States: Sepassi et al. (2023)
Relevance: Evaluates letermovir prophylaxis against pre-emptive valganciclovir for cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients in the United States from a health care payer perspective, an antiviral model in a transplant population, one of the subgroups reported for PRIOH-1 Part C.
“A publicly available decision tree model was constructed using a commercial third-party payer perspective to simulate an allo-HCT recipient’s clinical trajectory in the first-year post-transplant, followed by entry to a Markov model to simulate years 2 through 10.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The aim of this study was to assess the cost effectiveness of letermovir prophylaxis with the option for subsequent pre-emptive therapy (PET) for the prevention of cytomegalovirus (CMV) infection compared with a PET-only scenario in adult allogeneic hematopoietic stem cell transplant (allo-HCT) recipients in the United States over a 10-year time horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs and utility benefits of survival were annually discounted using a 3% rate, as recommended by the Second Panel on Cost-Effectiveness in Health and Medicine” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with PET alone, letermovir prophylaxis was projected to increase life-years per person (4.99 vs. 4.70 life-years), and increase QALYs (3.29 vs. 3.08) and costs (US$83.411 vs. US$70,698), yielding an ICER of US$59,356 per QALY gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PSA generated a mean ICER of US$75,497 per QALY gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 57.1% of the PSA simulations, letermovir was a cost-effective option using a willingness-to-pay threshold of US$100,000 per QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Letermovir prophylaxis versus no prophylaxis with pre-emptive therapy for cytomegalovirus in allogeneic hematopoietic cell transplant recipients, United States: Alsumali et al. (2021)
Relevance: Evaluates letermovir prophylaxis against pre-emptive therapy for cytomegalovirus in allogeneic hematopoietic cell transplant recipients in the United States, an antiviral model in a transplant population, one of the subgroups reported for PRIOH-1 Part C.
Access: Full text not retrieved
Not quoted: The time horizon, discount rate, and cost year are reported in the full text, which this page does not quote.
“To evaluate the cost-effectiveness of letermovir versus no prophylaxis for the prevention of cytomegalovirus infection and disease in adult cytomegalovirus-seropositive allogeneic hematopoietic cell transplantation (allo-HCT) recipients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A decision model for 100 patients was developed to estimate the probabilities of cytomegalovirus infection, cytomegalovirus disease, various other complications, and death in patients receiving letermovir versus no prophylaxis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The probabilities of clinical outcomes were based on the pivotal phase 3 trial of letermovir use for cytomegalovirus prophylaxis versus placebo in adult cytomegalovirus-seropositive recipients of an allo-HCT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this model, the use of letermovir prophylaxis would lead to an increase of QALYs (619) and direct medical cost ($1 733 794) compared with no prophylaxis (578 QALYs; $710 300) in cytomegalovirus-seropositive recipients of an allo-HCT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Letermovir use for cytomegalovirus prophylaxis was a cost-effective option versus no prophylaxis with base-case analysis ICER $25 046/QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The probabilistic sensitivity analysis showed a 92% probability of letermovir producing an ICER below the commonly accepted willingness-to-pay threshold of $100 000/QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights
Utility weights from analyses of Hovilpri (pritelivir and AIC316)
No evidence found.
Utility weights for the same indication
No evidence found.
Utility weights for the same disease in other populations or settings
Utility weights for mild, moderate, and severe maternal herpes simplex virus infection, genital herpes in pregnancy: Chatroux et al. (2021)
Relevance: Utilities for mild, moderate, and severe maternal herpes simplex virus infection from an analysis of pregnant women with genital herpes, as severity states of adult mucocutaneous herpes simplex infection.
Access: Not open access
Not quoted: The utility weights are reported in the full text, which is closed access.
“Outcomes included mild, moderate, and severe neonatal HSV, neonatal death, costs, and quality-adjusted life-years (QALYs) for both the woman and neonate.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Probabilities, utilities, and costs were derived from the literature, and we used a willingness-to-pay threshold of $100,000 per QALY.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights for related diseases and analogous treatments
Utility weights for cytomegalovirus infection without and with relapse after allogeneic hematopoietic stem cell transplantation: Qiu et al. (2024)
Relevance: Utilities for cytomegalovirus infection without and with relapse in allogeneic hematopoietic stem cell transplant recipients, an analogue for the recurrence that a model of refractory herpes simplex virus infection in transplant recipients would include.
Access: Not open access
Not quoted: The utility weights are reported in the full text, which is closed access.
“The cost of allo-HSCT recipients in a teaching hospital was collected, and a cost-effectiveness analysis using a decision tree combined with Markov model was completed from the perspective of allo-HSCT recipients over a lifetime horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights in the first and later years after allogeneic hematopoietic stem cell transplantation with letermovir prophylaxis or pre-emptive therapy, cytomegalovirus infection: Sepassi et al. (2023)
Relevance: EQ-5D utilities in the first year and later years after allogeneic hematopoietic stem cell transplantation with cytomegalovirus prophylaxis or pre-emptive therapy, a baseline for the transplant recipients enrolled in PRIOH-1 Part C.
“Health utilities included in our analysis were collected using data from a phase III clinical trial that used the EQ-5D-3L scale with UK tariffs to extract utility scores for both letermovir and placebo groups at baseline (immediately post-transplant), week 14, week 24, and week 48” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights in the first year after allogeneic hematopoietic cell transplantation with and without letermovir prophylaxis, cytomegalovirus infection: Alsumali et al. (2021)
Relevance: Utilities in the first year after allogeneic hematopoietic cell transplantation with and without letermovir prophylaxis, a baseline for the transplant recipients enrolled in PRIOH-1 Part C.
Access: Full text not retrieved
Not quoted: The utility weights are reported in the full text, which this page does not quote.
Utility weights for valganciclovir prophylaxis, cytomegalovirus disease, transplant rejection, graft failure, and dialysis after kidney transplantation: Blumberg et al. (2010)
Relevance: Utilities for cytomegalovirus disease, valganciclovir prophylaxis, acute rejection, graft failure, and dialysis after kidney transplantation, analogue states for transplant recipients with herpesvirus infection.
Access: Not open access
Not quoted: The utility weights are reported in the full text, which is closed access.
“An economic model was designed to simulate long-term costs and outcomes of prolonged prophylaxis with valganciclovir (200 vs. 100 days) in a cohort of 10,000 high-risk renal transplant patients over 5 and 10 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The first year of the model was based on the results of the Improved Protection Against CMV in Transplant trial and the extension to the long-term periods (5 and 10 years); and quality of life data were based on evidence retrieved through a systematic literature search.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Search strategy
| Dataset | Query | Results |
|---|---|---|
| Ratios | pritelivir OR AIC316 OR Hovilpri | 0 |
| Methods | pritelivir | 0 |
| Ratios | foscarnet OR cidofovir | 1 |
| Methods | "herpes simplex" OR "genital herpes" OR "herpes labialis" OR HSV | 10 |
| Ratios | acyclovir OR aciclovir OR valacyclovir OR valaciclovir OR famciclovir | 58 |
| Ratios | maribavir OR "refractory cytomegalovirus" OR "resistant cytomegalovirus" | 22 |
| Methods | cytomegalovirus AND transplant | 13 |
| Weights | "herpes simplex" OR "genital herpes" OR HSV OR "herpes labialis" OR "cold sore" | 33 |
| Ratios | herpes OR mucocutaneous | 386 |
| Weights | nephrotoxicity OR "acute kidney injury" OR "renal toxicity" | 140 |
| Ratios | "cytomegalovirus retinitis" OR "CMV retinitis" | 13 |
| Weights | cytomegalovirus AND (transplant OR "stem cell") | 47 |
| Ratios | imiquimod OR trifluridine | 36 |
| Ratios | "acyclovir-resistant" OR "acyclovir resistant" OR "antiviral resistance" | 4 |